Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.

Author: JoJolkis Faera
Country: Bosnia & Herzegovina
Language: English (Spanish)
Genre: Business
Published (Last): 21 December 2014
Pages: 164
PDF File Size: 17.84 Mb
ePub File Size: 10.70 Mb
ISBN: 686-9-19898-486-7
Downloads: 17297
Price: Free* [*Free Regsitration Required]
Uploader: Fauktilar

ABRAXANE | Full Prescribing Information

In an exploratory analysis, the pii risk of death for various patient subgroups was estimated using Cox proportional hazards regression. Peripheral neuropathy induced by paclitaxel: Eligible patients for this study included all women with mbc who were treated with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre.

Table i summarizes patient demographics and treatment characteristics.

Find articles by N. Albumin-bound paclitaxel ab-pac versus docetaxel for first-line treatment of metastatic breast cancer mbc: Nab-paclitaxel is a colloidal suspension of paclitaxel and human serum albumin that can be administered without premedication Abraxane PI, Abraxane PM: Abstract Abarxane Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer mbc.

In addition, it has been suggested that the Cremophor solvent used in the preparation of paclitaxel may have a direct negative effect on the antitumour properties of that sbraxane Treatment with nab-paclitaxel was well tolerated.


Data were collected retrospectively on a select group of patients who received nab-paclitaxel if they had private insurance coverage or met the eligibility criteria for the Ontario New Drug Funding Program, creating a potential for selection bias. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Grade 2 fatigue was reported in 4 patients 9.

Pharmacological effects of formulation vehicles: Median survivals were 7. Regardless of the schedule of administration, women who experienced clinical benefit from nab-paclitaxel lived significantly longer than those who did not achieve clinical benefit [ TABLE II Clinical outcomes data in abrxaane with metastatic breast cancer receiving nab-paclitaxel on a weekly qw and everyweeks q3w schedule.

ABRAXANE – Prescribing Information

Nab-paclitaxel was well tolerated, with the primary toxicity being mild sensory neuropathy. The remaining authors have no financial conflicts of interest to disclose. Our clinical wbraxane demonstrates that most women treated with nab-paclitaxel experienced some clinical benefit. This article has been cited by other articles in PMC. The results of a randomized phase ii study in women with mbc suggest that weekly dosing of nab-paclitaxel qw: J Natl Cancer Inst.

In this group, mean age was 57 years range: SD has received research support from Celgene Canada, but no compensation was received for the preparation of the abraxan manuscript.

In the Cox proportional hazards analysis, achievement of clinical benefit hr: Paclitaxel is anraxane by the formation of plasma Cremophor EL micelles, which can cause reduced drug clearance, nonlinear pharmacokinetics, and free drug fraction Clinical benefit was evaluable in 42 patients. Find articles by M. Sensory neuropathy was the primary toxicity Patients who had received taxane docetaxel or paclitaxel chemotherapy adjuvant or metastatic setting abarxane receiving nab-paclitaxel were also included.


Demographic and clinical abraxanr are summarized descriptively as means, medians, or proportions. Methods Women with mbc treated with single-agent nab-paclitaxel between June and December were included in this analysis. Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil—based paclitaxel in women with breast cancer.

Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract ] J Clin Oncol. Several limitations in the present study need to be acknowledged.

Clinical Benefit Radiologic and clinical assessments were performed at the discretion of the treating physician. Articles from Current Oncology are provided here courtesy of Multimed Inc. Support Center Support Center.

Eligibility Criteria Eligible patients for this study included all women with mbc who were treated with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre.